

# John R Nelson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8356447/publications.pdf>

Version: 2024-02-01

16  
papers

728  
citations

933447

10  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

880  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma fatty acid profiles: Relationships with sex, age, and state-reported heart disease mortality rates in the United States. <i>Journal of Clinical Lipidology</i> , 2022, 16, 184-197.	1.5	6
2	Differentiating EPA from EPA/DHA in cardiovascular risk reduction. <i>American Heart Journal Plus</i> , 2022, 17, 100148.	0.6	4
3	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. <i>Cardiovascular Research</i> , 2021, 117, 1070-1077.	3.8	45
4	The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. <i>Postgraduate Medicine</i> , 2021, 133, 28-41.	2.0	10
5	EPA's pleiotropic mechanisms of action: a narrative review. <i>Postgraduate Medicine</i> , 2021, 133, 1-14.	2.0	22
6	Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography. <i>Cardiovascular Research</i> , 2020, 116, 479-482.	3.8	38
7	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. <i>European Heart Journal</i> , 2020, 41, 3925-3932.	2.2	257
8	Association of high-density lipoprotein levels with baseline coronary plaque volumes by coronary CTA in the EVAPORATE trial. <i>Atherosclerosis</i> , 2020, 305, 34-41.	0.8	7
9	Relationship between Lipid Levels and Coronary Atherosclerotic Plaque Scores by Coronary Computed Tomography Angiography (CTA) in Subjects with Elevated Triglycerides. <i>Journal of Clinical Lipidology</i> , 2019, 13, e27.	1.5	1
10	Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. <i>Clinical Cardiology</i> , 2018, 41, 13-19.	1.8	63
11	Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. <i>Vascular Pharmacology</i> , 2017, 91, 1-9.	2.1	63
12	Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?. <i>Postgraduate Medicine</i> , 2017, 129, 822-827.	2.0	22
13	A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. <i>Journal of Medical Economics</i> , 2016, 19, 1003-1010.	2.1	6
14	History and future of omega-3 fatty acids in cardiovascular disease. <i>Current Medical Research and Opinion</i> , 2016, 32, 301-311.	1.9	29
15	Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. <i>Atherosclerosis</i> , 2015, 242, 357-366.	0.8	144
16	A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL3+IDL]). <i>Lipids in Health and Disease</i> , 2013, 12, 55.	3.0	11